Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases

Table 3

Univariable analysis of factors associated with improved median overall survival.

	Univariable
	HR (95% CI)	value
Age (continuous)	1.01 (0.98–1.04)	0.59
Gender		0.88
Female	Reference (1.00)
Male	1.06 (0.50–2.28)
ECOG at Y-90 treatment
0	Reference (1.00)
1	1.64 (0.66–4.13)	0.29
2	1.25 (0.15–10.42)	0.84
Tumor differentiation
Well	Reference (1.00)
Moderate	2.23 (0.89–5.59)	0.09
Poor	13.29 (1.42–124.41)	0.02
Ki67
≤2	Reference (1.00)
3–20	1.95 (0.77–4.79)	0.16
>20	15.56 (1.50–160.98)	0.02
Extrahepatic metastases	2.14 (0.97–4.71)	0.06
Hepatic tumor burden
<33%	Reference (1.00)	0.46
33–66%	2.01 (0.60–6.78)	0.26
>66%	1.32 (0.26–6.60)	0.74
Baseline CgA (continuous)	1.00	0.16
Previous local therapies	0.79 (0.33–1.88)	0.59
Previous SSA	0.87 (0.39–1.96)	0.74
Previous systemic therapies	1.56 (0.72–3.37)	0.26
Previous surgery	0.42 (0.19–0.91)	0.03

HR = hazard ratio; ECOG = Eastern Cooperative Oncology Group performance status; CgA = chromogranin A; SSA = somatostatin analogue.